Table 6. Logistic regression model of factors associated with exposure to triad combination of PP, PIM and DDI.
| Variables | Unadjusted OR (95%CI) | P- value | Adjusted ORa (95%CI) | P- value |
|---|---|---|---|---|
| Patient characteristics | ||||
| Age | 0.99 (0.97–1.02) | 0.790 | ||
| Female | 0.81 (0.55–1.19) | 0.279 | ||
| Short ADL scale | 1.03 (0.99–1.07) | 0.170 | ||
| Premorbid IADLs | 1.02 (1.00–1.04) | 0.036 | ||
| Number of comorbidities | 1.19 (1.07–1.31) | 0.001 | ||
| Diabetes mellitus | 1.88 (1.16–3.07) | 0.011 | ||
| Coronary artery disease | 1.56 (1.03–2.38) | 0.037 | ||
| Atrial fibrillation | 2.07 (1.27–3.39) | 0.004 | 2.12 (1.93–3.96) | 0.019 |
| Osteoporosis | 1.76 (1.04–3.01) | 0.037 | ||
| Medications characteristics | ||||
| A02 Drugs for acid related disorders | 1.65 (1.09–2.49) | 0.018 | ||
| A10 Drug used in diabetes | 2.03 (1.16–3.57) | 0.014 | ||
| A12 Mineral supplements | 1.74 (1.16–2.62) | 0.008 | ||
| C01 Cardiac therapy | 3.99 (2.30–6.95) | <0.001 | 3.49 (1.76–6.92) | <0.001 |
| C03 Diuretics | 2.43 (1.50–3.93) | <0.001 | ||
| C09 Agents acting on the renin- angiotensin system | 1.68 (1.13–2.49) | 0.011 | ||
| C10 Lipid modifying agents | 1.71 (1.14–2.56) | 0.010 | ||
| H03 Thyroid therapy | 1.94 (1.07–3.54) | 0.030 | ||
| N03 Antiepileptics | 2.64 (1.19–5.83) | 0.016 | ||
| N05 Psycholeptics | 4.88 (3.15–7.55) | <0.001 | 7.09 (4.23–11.87) | <0.001 |
| N06 Psychoanaleptics | 2.63 (1.70–4.05) | <0.001 | 2.41 (1.44–4.03) | 0.001 |
a Adjusted for age, sex, number of comorbidities, short ADL scale, premorbid IADLs and significant variable from unadjusted model.
Data are presented as odds ratio (95% confidence interval).
Abbreviations: ADL, activities of daily living; IADL, instrumental ADL; OR, odds ratio; CI, confidence interval.